Moorkens, Evelien ;
Godman, Brian ;
Huys, Isabelle...
Moorkens , E , Godman , B , Huys , I , Hoxha , I , Malaj , A , Keuerleber , S , Stockinger , S , Mörtenhuber , S , Dimitrova , M , Tachkov , K , Vončina , L , Palčevski , V V , Achniotou , G , Slabý , J , Popelková , L , Kohoutová , K , Bartels , D , Laius , O , Martikainen , J E , Selke , G W , Kourafalos , V , Magnússon , E , Einarsdóttir , R , Adams , R , Joppi , R , Allocati , E , Jakupi , A , Viksna , A , Greičiūtė-Kuprijanov , I , Vella Bonanno , P , Suttorp , V , Melien , Ø , Plisko , R , Mardare , I , Meshkov , D , Novakovic , T , Fürst , J , Zara , C , Marković-Peković , V , Grubiša , N , Befrits , G , Puckett , R & Vulto , A G 2021 , ' The Expiry of Humira ® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe : An Overview of Pricing and National Policy Measures ' , Frontiers in Pharmacology , vol. 11 , 591134 . https://doi.org/10.3389/fphar.2020.591134.
,
2021
